scholarly journals Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control

2004 ◽  
Vol 19 (5) ◽  
pp. 1211-1214 ◽  
Author(s):  
A.J. Carlin
Keyword(s):  
Bone Mineral Density ◽  
Molecular Weight ◽  
Observational Study ◽  
Bone Mineral ◽  
Low Molecular Weight Heparin ◽  
Prospective Observational Study ◽  
Low Molecular Weight ◽  
Mineral Density

P-079 Long term use of low-molecular-weight heparin during pregnancy does not affect postpartum bone mineral density

2013 ◽  
Vol 131 ◽  
pp. S97
Author(s):  
G. Mitic ◽  
A. Novakov-Mikic ◽  
J. Novakovic-Paro ◽  
D. Popov ◽  
S. Novakovic-Anucin ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Molecular Weight ◽  
Bone Mineral ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Mineral Density

P-007: Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density

2017 ◽  
Vol 151 ◽  
pp. S111-S112
Author(s):  
P. Galambosi ◽  
V. Hiilesmaa ◽  
V.M. Ulander ◽  
L. Laitinen ◽  
A. Tiitinen ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Molecular Weight ◽  
Bone Mineral ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Mineral Density

scholarly journals Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density

2016 ◽  
Vol 143 ◽  
pp. 122-126 ◽  
Author(s):  
Päivi Galambosi ◽  
Vilho Hiilesmaa ◽  
Veli-Matti Ulander ◽  
Leena Laitinen ◽  
Aila Tiitinen ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Molecular Weight ◽  
Bone Mineral ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight ◽  
Mineral Density

Patients’ experience and compliance with extended low molecular weight heparin prophylaxis post-surgery for gynecological cancer: a prospective observational study

2019 ◽  
Vol 29 (4) ◽  
pp. 802-809 ◽  
Author(s):  
Zibi Marchocki ◽  
Lucy Norris ◽  
Sharon O'Toole ◽  
Noreen Gleeson ◽  
Feras Abu Saadeh
Keyword(s):  
Molecular Weight ◽  
Side Effects ◽  
Observational Study ◽  
Low Molecular Weight Heparin ◽  
Prospective Observational Study ◽  
Patient Choice ◽  
Gynaecological Cancer ◽  
Low Molecular Weight ◽  
Tablet Form ◽  
Heparin Prophylaxis

ObjectiveGynaecological cancer patients have a high risk of developing venous thromboembolism (VTE). There is limited information on patient experience and compliance with an extended low molecular weight heparin prophylaxis in this setting. The aim of this study was to assess patient compliance, satisfaction and experience with the extended low molecular weight heparin prophylaxis after major surgery for gynaecological cancer.MethodsThis was a prospective observational study conducted in a large tertiary center for gynaecological cancer between July 2017-March 2018. Consecutive patients undergoing surgery for gynaecological cancer who received low molecular weight heparin prophylaxis for four weeks following surgery were recruited. All participants received a log book to record all injections, side effects, and questionnaire to be completed at the end of the study.ResultsA total of 106 patients completed and returned the VTE prophylaxis logbook and questionnaire. Sixty-six (62%) patients received low molecular weight heparin for 28 days, twenty-five (24%) for 26-27 days, and 15 (14%) for less than 26 days. The median number of days of therapy was 28 days (range; 12-28 days). Reasons for missed or stopped injections included: forgetfulness(n=12), medical procedures (n=6), pain (n=5), incorrect prescription (n=4), patient choice (n=3), cost (n=2), physician request (n=2), non-availability of person administering the injections (n=1) or unknown (n=5). Sixty-one (58%) patients self-administered the injections. Patients who had the injection performed by a third person were twice as likely to experience pain compared to patients who self-administered (OR 2.81, p=0.003). Eighty-nine (84%) patients self-reported side effects during low molecular weight heparin prophylaxis including: bruising (75%), pain after injections (49%), itchiness (9%), swelling (9%) or other (8%). Although 83 (78%) patients were satisfied with injections, 91 (86%) admitted they would much prefer a tablet form.ConclusionsCompliance with standard recommended regimen of 28-days prophylaxis was completed by 62% of patients. Majority of patients (86%) reported a preference for a tablet form, if one was available.

Sign in / Sign up

Export Citation Format

Share Document